VRDN Stock Price and Chart NASDAQ:VRDN
- VRDN Viridian Therapeutics Inc
- Financial Performance
- Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
- Dow Jones Network
- Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
It can also be calculated by dividing the company’s Market Cap by the Net Profit. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Real-time analyst ratings, insider transactions, earnings data, and more. Viridian Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.
Pre-Market Earnings Report for March 8, 2023 : CPB, LTH, ABM … – Nasdaq
Pre-Market Earnings Report for March 8, 2023 : CPB, LTH, ABM ….
Posted: Tue, 07 Mar 2023 08:00:00 GMT [source]
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 11 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Viridian Therapeutics in the last year. The consensus among Wall Street equities research analysts is that investors should “buy” VRDN shares. 11 Wall Street research analysts have issued 1-year price objectives for Viridian Therapeutics’ shares. Their VRDN share price forecasts range from $40.00 to $51.00.
VRDN Viridian Therapeutics Inc
The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
These are established companies that reliably pay dividends. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Viridian Therapeutics has a news sentiment score of 0.93.
The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.
We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
Looking for Red-Hot Takeover Candidates? Here Are 2 Stocks on … – TipRanks
Looking for Red-Hot Takeover Candidates? Here Are 2 Stocks on ….
Posted: Mon, 05 Dec 2022 08:00:00 GMT [source]
In the past three months, Viridian Therapeutics insiders have sold 935.60% more of their company’s stock than they have bought. Specifically, they have bought $261,805.00 in company stock and sold $2,711,257.00 in company stock. Viridian Therapeutics has a short interest ratio (“days to cover”) of 6.7. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Viridian Therapeutics, Inc. delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Viridian Therapeutics, Inc. delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022.
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
These why people buy stocks cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareVRDN’s historical performanceagainst its industry peers and the overall market. One share of VRDN stock can currently be purchased for approximately $28.03. Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.
A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. The mean of analysts’ price targets for Viridian Therapeutics, Inc. points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr… Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.
It’s calculated by multiplying the current market price by the total number of shares outstanding. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody being developed for the potential treatment for patients with thyroid eye disease.
This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies. Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics.
Dow Jones Network
The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA. According to 9 analysts, the average rating for VRDN stock is “Strong Buy.” The 12-month stock price forecast is $42.56, which is an increase of 51.84% from the latest price. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share .
3 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Only 7 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. MarketBeat has tracked 2 news articles for Viridian Therapeutics this week, compared to 2 articles on an average week. In 2022, VRDN’s revenue was $1.77 million, a decrease of -40.20% compared to the previous year’s $2.96 million.
Intraday data delayed at least 15 minutes or per exchange requirements. Represents the company’s profit divided by the outstanding shares of its common stock. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.
Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting
It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts. Market cap, also known as market capitalization, is the total market value of a company.
Viridian Therapeutics, Inc. (VRDN) Stock Price Today, Quote & News – Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) Stock Price Today, Quote & News.
Posted: Tue, 02 Feb 2021 16:00:06 GMT [source]
https://1investing.in/ Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Viridian Therapeutics’ stock was trading at $29.21 on January 1st, 2023. Since then, VRDN stock has decreased by 4.0% and is now trading at $28.03. The P/E ratio of Viridian Therapeutics is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 8.28% of the outstanding shares of Viridian Therapeutics have been sold short. According to analysts’ consensus price target of $45.67, Viridian Therapeutics has a forecasted upside of 62.9% from its current price of $28.03.
- It attempts to reflect the cash profit generated by a company’s operations.
- We’d like to share more about how we work and what drives our day-to-day business.
- Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.
- A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
- There may be delays, omissions, or inaccuracies in the Information.
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.